Matches in DBpedia 2016-04 for { ?s ?p "5-Methoxy-2-aminoindane (MEAI, 5-MeO-AI, or Chaperon) is a psychoactive small molecule belonging to the aminoindane class with a mechanism of action described by one patent as being mediated by binding to the dopamine D3 receptor.It was first prepared by Schering AG in 1956. David Nutt and Amanda Feilding filed a patent application for the drug claiming that it gives people a pleasant intoxication as well as prevent binge drinking.MEAI has been available through grey market sources since 2011.At least 2 journalists tried it on themselves and reported to the public: Michael Slezak from New Scientist and Brie Traits from BBC3. Apparently, Nutt has also tried it himself.The idea of alcohol substitution got public attention a year prior to the announcement of chaperon but apparently, chaperon innovates in that it can be consumed together with alcohol without ill effect.MEAI is banned in some countries as a structural isomer of methcathinone."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- MEAI abstract "5-Methoxy-2-aminoindane (MEAI, 5-MeO-AI, or Chaperon) is a psychoactive small molecule belonging to the aminoindane class with a mechanism of action described by one patent as being mediated by binding to the dopamine D3 receptor.It was first prepared by Schering AG in 1956. David Nutt and Amanda Feilding filed a patent application for the drug claiming that it gives people a pleasant intoxication as well as prevent binge drinking.MEAI has been available through grey market sources since 2011.At least 2 journalists tried it on themselves and reported to the public: Michael Slezak from New Scientist and Brie Traits from BBC3. Apparently, Nutt has also tried it himself.The idea of alcohol substitution got public attention a year prior to the announcement of chaperon but apparently, chaperon innovates in that it can be consumed together with alcohol without ill effect.MEAI is banned in some countries as a structural isomer of methcathinone.".
- Q21098822 abstract "5-Methoxy-2-aminoindane (MEAI, 5-MeO-AI, or Chaperon) is a psychoactive small molecule belonging to the aminoindane class with a mechanism of action described by one patent as being mediated by binding to the dopamine D3 receptor.It was first prepared by Schering AG in 1956. David Nutt and Amanda Feilding filed a patent application for the drug claiming that it gives people a pleasant intoxication as well as prevent binge drinking.MEAI has been available through grey market sources since 2011.At least 2 journalists tried it on themselves and reported to the public: Michael Slezak from New Scientist and Brie Traits from BBC3. Apparently, Nutt has also tried it himself.The idea of alcohol substitution got public attention a year prior to the announcement of chaperon but apparently, chaperon innovates in that it can be consumed together with alcohol without ill effect.MEAI is banned in some countries as a structural isomer of methcathinone.".